tradingkey.logo
tradingkey.logo
Pesquisar

Genfit SA

GNFT
Adicionar à lista de desejos
4.850USD
0.0000.00%
Fechamento 07/02, 13:00ETCotações atrasadas em 15 min
741.27MValor de mercado
--P/L TTM

Mais detalhes de Genfit SA Empresa

Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.

Informações de Genfit SA

Código da empresaGNFT
Nome da EmpresaGenfit SA
Data de listagemDec 19, 2006
CEOPrigent (Pascal)
Número de funcionários180
Tipo de títulosDepository Receipt
Fim do ano fiscalDec 19
EndereçoParc Eurasante 885 avenue Eugene Avinee
CidadeLOOS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísFrance
Código postal59120
Telefone33320164000
Sitehttps://www.genfit.fr/
Código da empresaGNFT
Data de listagemDec 19, 2006
CEOPrigent (Pascal)

Executivos da empresa Genfit SA

Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Jean-Francois Mouney
Mr. Jean-Francois Mouney
Chairman of the Board of Directors
Chairman of the Board of Directors
--
--
Ms. Florence Sejourne
Ms. Florence Sejourne
Director, Representative of Biotech Avenir SAS
Director, Representative of Biotech Avenir SAS
--
--
Prof. Laurent Lannoo
Prof. Laurent Lannoo
Corporate Secretary, Director of Legal Affairs
Corporate Secretary, Director of Legal Affairs
--
--
Dr. Dean W. Hum, Ph.D.
Dr. Dean W. Hum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Catherine Larue, Ph.D.
Dr. Catherine Larue, Ph.D.
Independent Director
Independent Director
--
--
Mr. Pascal Prigent
Mr. Pascal Prigent
Chief Executive Officer
Chief Executive Officer
--
--
Mrs. Anne-Helene Monsellato
Mrs. Anne-Helene Monsellato
Independent Director
Independent Director
--
--
Ms. Katherine Bach Kalin
Ms. Katherine Bach Kalin
Independent Director
Independent Director
--
--
Mr. Eric Baclet
Mr. Eric Baclet
Independent Vice-Chairman of the Board of Directors
Independent Vice-Chairman of the Board of Directors
--
--
Mr. Jean-Christophe Marcoux
Mr. Jean-Christophe Marcoux
Chief Corporate Affairs Officer, Head of Investor Relations, Head of ESG
Chief Corporate Affairs Officer, Head of Investor Relations, Head of ESG
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Jean-Francois Mouney
Mr. Jean-Francois Mouney
Chairman of the Board of Directors
Chairman of the Board of Directors
--
--
Ms. Florence Sejourne
Ms. Florence Sejourne
Director, Representative of Biotech Avenir SAS
Director, Representative of Biotech Avenir SAS
--
--
Prof. Laurent Lannoo
Prof. Laurent Lannoo
Corporate Secretary, Director of Legal Affairs
Corporate Secretary, Director of Legal Affairs
--
--
Dr. Dean W. Hum, Ph.D.
Dr. Dean W. Hum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Catherine Larue, Ph.D.
Dr. Catherine Larue, Ph.D.
Independent Director
Independent Director
--
--
Mr. Pascal Prigent
Mr. Pascal Prigent
Chief Executive Officer
Chief Executive Officer
--
--

Perguntas frequentes

Quem são os cinco principais acionistas de Genfit SA?

Os cinco principais acionistas de Genfit SA são: Mr. Jean-Francois Mouney

Quantas instituições possuem ações da Genfit SA (GNFT)?

Em 2026Q1, 16 instituições possuíam ações da Genfit SA, com valor de mercado aproximado de 22.36K, representando 0.04% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -215235.00.